LEADER 01676nam  22004335  450 
001 9910254554503321
005 20200703085121.0
010   $a3-319-08982-X
024 7 $a10.1007/978-3-319-08982-9
035   $a(CKB)3710000000726801
035   $a(DE-He213)978-3-319-08982-9
035   $a(MiAaPQ)EBC4543255
035   $a(PPN)194380343
035   $a(EXLCZ)993710000000726801
100   $a20160607d2016      u|         0
101 0 $aeng
135   $aurnn|008mamaa
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aHandbook of Incretin-based Therapies in Type 2 Diabetes /$fedited by Stephen Gough
205   $a1st ed. 2016.
210  1$aCham :$cSpringer International Publishing :$cImprint: Adis,$d2016.
215   $a1 online resource (IX, 92 p. 20 illus., 16 illus. in color.) 
311   $a3-319-08981-1 
320   $aIncludes bibliographical references at the end of each chapters.
327   $aIntroduction and disease overview -- Incretin hormones as a target for therapy -- Glucagon-like peptide receptor agonists -- Dipeptidyl peptidase-4 inhibitors -- Global position and recommendations for use -- Future and emerging therapies. .
330   $a .
606   $aDiabetes
606   $aDiabetes$3https://scigraph.springernature.com/ontologies/product-market-codes/H33045
615  0$aDiabetes.
615 14$aDiabetes.
676   $a616.462
676   $a616.46
702   $aGough$b Stephen$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910254554503321
996   $aHandbook of Incretin-based Therapies in Type 2 Diabetes$92540564
997   $aUNINA